Investigation of clinical usefulness of serum biomarker for patients with IBD. And analyse correlations between efficacy of GMA and serum biomarker.

Investigation of clinical usefulness of serum biomarker for patients with IBD. And analyse correlations between efficacy of GMA and serum biomarker. - Correlations between efficacy of GMA and serum biomarker for patients with IBD.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019864

Enrollment

Registered

2016-01-04

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative colitis Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1:Patient who judged that GMA treatment was appropriate along guidelines on Ministry of Health, Labour and Welfare. 2:Patient who are older than 20 years old. 3:Patiens who agreed to precipitate in this study after being informed of the study protocol.

Exclusion criteria

Exclusion criteria: 1:Patient with granulocytopenia (granulocyte count < 2,000/mm3). 2:Patient with or suspected to have severe infection. 3:Patient who judged to be exclusive by investigators for a certain reason.

Design outcomes

Primary

Measure	Time frame
Clinical response rate. UC:Mayo score >= 30% decrease partial Mayo score >= 30% decrease CD:CDAI score >= 70 decrease	—

Secondary

Measure	Time frame
Clinical response rate. UC:Mayo score <= 2 partial Mayo score<= 2 CD:CDAI score<= 150	—

Countries

Japan

Contacts

Public ContactTaro Osada

Juntendo University Department of Gastroenterology

otaro@juntendo.ac.jp03-3813-3111

Outcome results